The unique potential for noninvasive imaging in modernizing drug development and in transforming therapeutics: PET/MRI/MRS

Pharmaceutical Research

Volumn 28, Issue 3, 2011, Pages 490-493

  Wolf, Walter ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 11; DIHYDROFLUOROURACIL; FLUORINE; FLUORINE 18; FLUOROURACIL; THYMIDYLATE SYNTHASE;

COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG INDUSTRY; DRUG LABELING; DRUG METABOLISM; DRUG RESEARCH; DRUG STRUCTURE; HUMAN; NON INVASIVE PROCEDURE; NONHUMAN; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHARMACODYNAMICS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOLID TUMOR;

ANIMALS; DRUG DISCOVERY; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; PHARMACEUTICAL PREPARATIONS; POSITRON-EMISSION TOMOGRAPHY; SOCIAL CHANGE;

EID: 79952485613     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-010-0293-5     Document Type: Note

References (15)

1. Catana C, Wu Y, Judenhofer MS, Qi J, Pichler BJ, Cherry SR. Simultaneous acquisition of multislice PET and MR Images: initial results with a MR-compatible PET scanner. J Nucl Med. 2006;47:1968-76. (Pubitemid 47544984)
2. Judenhofer MS, Wehrl HF, Newport DF, Catana C, Siegel SB, Becker M, et al. Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nat Med. 2008;14:459-65. (Pubitemid 351499385)
3. Pichler BJ, Kolb A, Nägele T, Schlemmer H-P. PET/MRI: Paving the Way for the Next Generation of Clinical Multimodality Imaging Applications. J Nucl Med. 2010;51:333-6.
4. Peremans K, De Spiegeleer B, Buntinx E, Dobbeleir A, Vermeire S, Vandermeulen E, et al. Evaluation of serotonin-2A receptor occupancy with 123I-5-I-R91150 and single-photon emission tomography before and after low-dose pipamperone administration in the canine brain. Nucl Med Commun. 2008;29:724-9.
5. Hillman BJ, Goldsmith JC. The Uncritical Use of High-Tech Medical Imaging. N Engl J Med. 2010;363:4-6.
6. Heidelberger C, Chaudhuri NK, Danneberg P, Mooren D, Griesbach L, Duschinsky R, et al. Fluorinated Pyrimidines, A New Class of Tumour-Inhibitory Compounds. Nature. 1957;179:663-6.
7. Pinedo HM, Peters GF. Fluorouracil: biochemistry and pharmacology. J Clin Oncol. 1988;6:1653-64.
8. Rustum YM. Fluoropyrimidines in Cancer Therapy. Totowa: Humana Press; 2003.
9. Shani J, Wolf W. A Model of Prediction of Chemotherapy Response to 5-FU in Sensitive versus Resistant Lymphocytic Leukemia in Mice. Cancer Res. 1977;37:2306-8.
10. Young D, Vine E, Ghanbarpour A, Shani J, Siemsen JK, Wolf W. Metabolic and Distribution Studies with Radiolabeled 5-Fluorouracil. Nucl Med. 1982;21:1-7. (Pubitemid 12135883)
11. Wolf W, Presant CA, Servis KL, El-Tahtawy A, Albright MJ, Barker PB, et al. Tumor Trapping of 5-Fluorouracil: in vivo 19F - NMR Spectroscopic Pharmacokinetics in Tumor-bearing Humans and rabbits. Proc Natl Acad Sci. 1990;87:492-6.
12. Presant CA, Wolf W, Waluch V, Wiseman C, Kennedy P, Blayney D, et al. Association of the Intratumoral Pharmacokinetics of 5-Fluorouracil with Clinical Response: an In-Vivo 19F Nuclear Magnetic Resonance Study. Lancet. 1994;343:1184-7.
13. Wolf W, Presant CA, Waluch V. Noninvasive Studies of Fluoropyrimidines. In Fluoropyrimidines in Cancer Therapy. In: Youcef Rustum, editor. Cancer Drug Discovery and Development series. Totowa: Humana Press; 2003.
14. Stevens AN, Morris PG, Iles RA, Sheldon PW, Griffiths JR. 5-Fluorouracil metabolism monitored in vivo by of 5-FU catabolites in human liver. Br J Cancer. 1984;50:113-7. (Pubitemid 14092653)
15. Wolf W, Presant CA, Waluch V. 19F-MRS Studies of Fluorinated Drugs in Humans. Adv Drug Deliv Rev. 2000;41:5-74.